Nektar Therapeutics (NKTR) Share-based Compensation (2010 - 2026)

Nektar Therapeutics' Share-based Compensation history runs 17 years deep, the most recent figure standing at $3.4 million for Q1 2026.

• On a quarterly basis, Share-based Compensation fell 13.93% year-over-year to $3.4 million in Q1 2026; TTM through Mar 2026 was $12.1 million, a 37.95% decrease from a year earlier, with the FY2025 full-year figure at $12.6 million, down 41.47% from the prior year.
• Share-based Compensation improved to $3.4 million in Q1 2026 per NKTR's latest filing, from $2.2 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $21.0 million in Q1 2022 and bottomed at $2.2 million in Q4 2025.
• The 5-year median for Share-based Compensation is $6.0 million (2024), against an average of $7.5 million.
• Across the five-year window, Share-based Compensation fell 12.29% in 2022 and slumped 54.34% in 2025, its largest moves.
• Year by year, Share-based Compensation stood at $12.7 million in 2022, then sank by 43.05% to $7.3 million in 2023, then plunged by 33.79% to $4.8 million in 2024, then slumped by 54.34% to $2.2 million in 2025, then soared by 52.99% to $3.4 million in 2026.
• Per Business Quant, the three latest NKTR Share-based Compensation figures stand at $3.4 million (Q1 2026), $2.2 million (Q4 2025), and $3.1 million (Q3 2025).